557 related articles for article (PubMed ID: 28297619)
1. Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.
Kennedy JA; Ebert BL
J Clin Oncol; 2017 Mar; 35(9):968-974. PubMed ID: 28297619
[TBL] [Abstract][Full Text] [Related]
2. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
Ganguly BB; Banerjee D; Agarwal MB
Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and Pathogenesis of Myelodysplastic Syndrome.
Rotter LK; Shimony S; Ling K; Chen E; Shallis RM; Zeidan AM; Stahl M
Cancer J; 2023 May-Jun 01; 29(3):111-121. PubMed ID: 37195766
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
Nakajima H
Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
[TBL] [Abstract][Full Text] [Related]
5. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
[TBL] [Abstract][Full Text] [Related]
6. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
Babushok DV; Bessler M; Olson TS
Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
[TBL] [Abstract][Full Text] [Related]
7. Genetics of MDS.
Ogawa S
Blood; 2019 Mar; 133(10):1049-1059. PubMed ID: 30670442
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help?
Chung SS
Curr Opin Hematol; 2016 Mar; 23(2):79-87. PubMed ID: 26825694
[TBL] [Abstract][Full Text] [Related]
9. Genetics of myelodysplastic syndromes: new insights.
Graubert T; Walter MJ
Hematology Am Soc Hematol Educ Program; 2011; 2011():543-9. PubMed ID: 22160087
[TBL] [Abstract][Full Text] [Related]
10. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
Duncavage EJ; Tandon B
Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
[TBL] [Abstract][Full Text] [Related]
11. [MDS: Recent progress in molecular pathogenesis and clinical aspects].
Harada H
Rinsho Ketsueki; 2017; 58(10):1941-1950. PubMed ID: 28978836
[TBL] [Abstract][Full Text] [Related]
12. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.
Sperling AS; Gibson CJ; Ebert BL
Nat Rev Cancer; 2017 Jan; 17(1):5-19. PubMed ID: 27834397
[TBL] [Abstract][Full Text] [Related]
13. The molecular pathogenesis of the myelodysplastic syndromes.
Pellagatti A; Boultwood J
Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
[TBL] [Abstract][Full Text] [Related]
14. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
15. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
Harada H; Harada Y; Kimura A
Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876
[TBL] [Abstract][Full Text] [Related]
16. [Epigenetic dysregulation in myelodysplastic syndromes].
Sashida G
Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
[TBL] [Abstract][Full Text] [Related]
17. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
Babushok DV; Bessler M
Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
[TBL] [Abstract][Full Text] [Related]
18. Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges.
Caponetti GC; Bagg A
Int J Lab Hematol; 2020 Dec; 42(6):671-684. PubMed ID: 32757473
[TBL] [Abstract][Full Text] [Related]
19. The genetic and molecular pathogenesis of myelodysplastic syndromes.
Shallis RM; Ahmad R; Zeidan AM
Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
[TBL] [Abstract][Full Text] [Related]
20. Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment.
Stosch JM; Heumüller A; Niemöller C; Bleul S; Rothenberg-Thurley M; Riba J; Renz N; Szarc Vel Szic K; Pfeifer D; Follo M; Pahl HL; Zimmermann S; Duyster J; Wehrle J; Lübbert M; Metzeler KH; Claus R; Becker H
Br J Haematol; 2018 Sep; 182(6):830-842. PubMed ID: 29974943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
